GlassScriptPhysician profile
David Piselli
NPI 1982333845
$2,721.82
in general payments reported to CMS, 2019-2025
23 companies · $643 in 2025
The $643 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $1,071 · 2024: $564 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,177.62 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $451.65 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Supernus Pharmaceuticals, INC. | $336.43 | 2024-2025 | Qelbree |
| Abbvie INC. | $281.36 | 2022-2024 | |
| Novo Nordisk INC | $245.98 | 2022-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $204.25 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.26 | 2022-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $167.62 | 2022-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.16 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $117.68 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Astellas Pharma US INC | $99.99 | 2023 | |
| Corium, LLC | $88.71 | 2025 | Azstarys |
| Amgen INC. | $75.12 | 2023 | Repatha, Otezla |
| Cmp Pharma, INC. | $59.99 | 2023 | Carospir, Tadliq, Norliqva |
| Sanofi-Aventis U.S. LLC | $52.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $35.92 | 2024-2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $35.69 | 2022-2024 | Quviviq |
| Pfizer INC. | $25.37 | 2024 | |
| Sumitomo Pharma America, INC. | $24.80 | 2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $23.07 | 2022 | |
| Ardelyx, INC. | $21.22 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $21.18 | 2024 | Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $19.54 | 2023 | |
| Heartflow, INC. | $16.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Piselli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.